FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162849130> ?p ?o ?g. }

• W2162849130 endingPage "177" @default.
• W2162849130 startingPage "171" @default.
• W2162849130 abstract "ABSTRACT The therapeutic efficacy of BAL9141 (formerly Ro 63-9141), a novel cephalosporin with broad in vitro activity that also has activity against methicillin-resistant Staphylococcus aureus (MRSA), was investigated in rats with experimental endocarditis. The test organisms were homogeneously methicillin-resistant S. aureus strain COL transformed with the penicillinase-encoding plasmid pI524 (COL Bla+) and homogeneously methicillin-resistant, penicillinase-producing isolate P8-Hom, selected by serial exposure of parent strain P8 to methicillin. The MICs of BAL9141 for these organisms (2 mg/liter) were low, and BAL9141was bactericidal in time-kill curve studies after 24 h of exposure to either two, four, or eight times the MIC. Rats with experimental endocarditis were treated in a three-arm study with a continuous infusion of BAL5788 (formerly Ro 65-5788), a carbamate prodrug of BAL9141, or with amoxicillin-clavulanate or vancomycin. The rats were administered BAL9141 to obtain steady-state target levels of 20, 10, and 5 mg of per liter or were administered either 1.2 g of amoxicillin-clavulanate (ratio 5:1) every 6 h or 1 g of vancomycin every 12 h at changing flow rates to simulate the pharmacokinetics produced in humans by intermittent intravenous treatment. Treatment was started 12 h after bacterial challenge and lasted for 3 days. BAL9141 was successful in the treatment of experimental endocarditis due to either MRSA isolate COL Bla+ or MRSA isolate P8-Hom at the three targeted steady-state concentrations and sterilized >90% of cardiac vegetations ( P < 0.005 versus controls; P < 0.05 versus amoxicillin-clavulanate and vancomycin treatment groups). These promising in vivo results with BAL9141 correlated with the high affinity of the drug for PBP 2a and its stability to penicillinase hydrolysis observed in vitro." @default.
• W2162849130 created "2016-06-24" @default.
• W2162849130 creator A5040104596 @default.
• W2162849130 creator A5046998679 @default.
• W2162849130 creator A5065258830 @default.
• W2162849130 creator A5074201837 @default.
• W2162849130 creator A5090366607 @default.
• W2162849130 date "2002-01-01" @default.
• W2162849130 modified "2023-10-16" @default.
• W2162849130 title "BAL9141, a Novel Extended-Spectrum Cephalosporin Active against Methicillin-Resistant <i>Staphylococcus aureus</i> in Treatment of Experimental Endocarditis" @default.
• W2162849130 cites W1541841780 @default.
• W2162849130 cites W1901734092 @default.
• W2162849130 cites W1973518692 @default.
• W2162849130 cites W1984324040 @default.
• W2162849130 cites W1987787460 @default.
• W2162849130 cites W2060777969 @default.
• W2162849130 cites W2062495428 @default.
• W2162849130 cites W2079889984 @default.
• W2162849130 cites W2079952184 @default.
• W2162849130 cites W2098900398 @default.
• W2162849130 cites W2109223863 @default.
• W2162849130 cites W2112967578 @default.
• W2162849130 cites W2113717321 @default.
• W2162849130 cites W2118094416 @default.
• W2162849130 cites W2123200119 @default.
• W2162849130 cites W2140777443 @default.
• W2162849130 cites W2161743604 @default.
• W2162849130 cites W2170496554 @default.
• W2162849130 cites W2317219869 @default.
• W2162849130 cites W2336324580 @default.
• W2162849130 doi "https://doi.org/10.1128/aac.46.1.171-177.2002" @default.
• W2162849130 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/126986" @default.
• W2162849130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11751129" @default.
• W2162849130 hasPublicationYear "2002" @default.
• W2162849130 type Work @default.
• W2162849130 sameAs 2162849130 @default.
• W2162849130 citedByCount "90" @default.
• W2162849130 countsByYear W21628491302012 @default.
• W2162849130 countsByYear W21628491302013 @default.
• W2162849130 countsByYear W21628491302014 @default.
• W2162849130 countsByYear W21628491302015 @default.
• W2162849130 countsByYear W21628491302017 @default.
• W2162849130 countsByYear W21628491302018 @default.
• W2162849130 countsByYear W21628491302019 @default.
• W2162849130 countsByYear W21628491302021 @default.
• W2162849130 countsByYear W21628491302022 @default.
• W2162849130 countsByYear W21628491302023 @default.
• W2162849130 crossrefType "journal-article" @default.
• W2162849130 hasAuthorship W2162849130A5040104596 @default.
• W2162849130 hasAuthorship W2162849130A5046998679 @default.
• W2162849130 hasAuthorship W2162849130A5065258830 @default.
• W2162849130 hasAuthorship W2162849130A5074201837 @default.
• W2162849130 hasAuthorship W2162849130A5090366607 @default.
• W2162849130 hasBestOaLocation W21628491302 @default.
• W2162849130 hasConcept C112705442 @default.
• W2162849130 hasConcept C126322002 @default.
• W2162849130 hasConcept C141071460 @default.
• W2162849130 hasConcept C176674119 @default.
• W2162849130 hasConcept C2775872228 @default.
• W2162849130 hasConcept C2777052132 @default.
• W2162849130 hasConcept C2778980435 @default.
• W2162849130 hasConcept C2779489039 @default.
• W2162849130 hasConcept C2779708577 @default.
• W2162849130 hasConcept C501593827 @default.
• W2162849130 hasConcept C523546767 @default.
• W2162849130 hasConcept C54355233 @default.
• W2162849130 hasConcept C64778159 @default.
• W2162849130 hasConcept C71924100 @default.
• W2162849130 hasConcept C86803240 @default.
• W2162849130 hasConcept C89423630 @default.
• W2162849130 hasConcept C98274493 @default.
• W2162849130 hasConceptScore W2162849130C112705442 @default.
• W2162849130 hasConceptScore W2162849130C126322002 @default.
• W2162849130 hasConceptScore W2162849130C141071460 @default.
• W2162849130 hasConceptScore W2162849130C176674119 @default.
• W2162849130 hasConceptScore W2162849130C2775872228 @default.
• W2162849130 hasConceptScore W2162849130C2777052132 @default.
• W2162849130 hasConceptScore W2162849130C2778980435 @default.
• W2162849130 hasConceptScore W2162849130C2779489039 @default.
• W2162849130 hasConceptScore W2162849130C2779708577 @default.
• W2162849130 hasConceptScore W2162849130C501593827 @default.
• W2162849130 hasConceptScore W2162849130C523546767 @default.
• W2162849130 hasConceptScore W2162849130C54355233 @default.
• W2162849130 hasConceptScore W2162849130C64778159 @default.
• W2162849130 hasConceptScore W2162849130C71924100 @default.
• W2162849130 hasConceptScore W2162849130C86803240 @default.
• W2162849130 hasConceptScore W2162849130C89423630 @default.
• W2162849130 hasConceptScore W2162849130C98274493 @default.
• W2162849130 hasIssue "1" @default.
• W2162849130 hasLocation W21628491301 @default.
• W2162849130 hasLocation W21628491302 @default.
• W2162849130 hasOpenAccess W2162849130 @default.
• W2162849130 hasPrimaryLocation W21628491301 @default.
• W2162849130 hasRelatedWork W2018382434 @default.
• W2162849130 hasRelatedWork W2068279471 @default.
• W2162849130 hasRelatedWork W2109417549 @default.
• W2162849130 hasRelatedWork W2125076516 @default.
• W2162849130 hasRelatedWork W2127397875 @default.

• next